Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Recruiting 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2Plasma cell 1

Conditions

Leukemia, Myeloid, Acute 428Precursor Cell Lymphoblastic Leukemia-Lymphoma 240Hematologic Neoplasms 214Leukemia, Lymphocytic, Chronic, B-Cell 184Myelodysplastic Syndromes 155Leukemia 130Lymphoma 91Lymphoma, Non-Hodgkin 82Leukemia, Myelogenous, Chronic, BCR-ABL Positive 71Multiple Myeloma 69Recurrence 59Neoplasms 54Leukemia, Myelomonocytic, Chronic 54Burkitt Lymphoma 48Myeloproliferative Disorders 46Leukemia, Biphenotypic, Acute 45Lymphoma, Large B-Cell, Diffuse 43Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 41Lymphoma, Mantle-Cell 40Hodgkin Disease 39Lymphoma, Follicular 33Lymphoma, B-Cell 33Leukemia, B-Cell 27Lymphoma, B-Cell, Marginal Zone 26Waldenstrom Macroglobulinemia 25Anemia, Refractory, with Excess of Blasts 25Primary Myelofibrosis 24Myelodysplastic-Myeloproliferative Diseases 21Hematologic Diseases 19Leukemia, Myeloid, Chronic-Phase 18

Interventions

gamma-Globulins 1Saline Solution 1Panzyga 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Agammaglobulinemia × Other hematologic neoplasm × 90 days × Clear all
NCT04502030 2026-06-04

Double-blind, Randomized, Placebo-controlled, Prospective Phase III Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients With Chronic Lymphocytic Leukemia ("PRO-SID" Study)

Octapharma

Phase 3 Completed
247 enrolled
LymphoidOther hematologic neoplasm

Agammaglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell

NCT05645107 2026-04-13

EXCELL

Grifols Therapeutics LLC

Phase 3 Recruiting
386 enrolled
LymphoidOther hematologic neoplasm

Agammaglobulinemia, Bacterial Infections, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡